Posters

Pentraxin levels in patients with age-related macular degeneration

Poster Details

First Author: S.Çalışkan TURKEY

Co Author(s):    O. Celikay   F. Ucar   T. Bicer   N. Kabatas   C. Gurdal                 

Abstract Details



Purpose:

We aimed to measure the plasma levels of long pentraxin (pentraxin 3 (PTX3) and short pentraxins (high sensitive C-reactive protein (hCRP) and serum amyloid P (SAP)) in age-related macular degeneration (ARMD) patients and to investigate the relationships between plasma levels and severity of the disease.

Setting:

Prospective, cross-sectional study

Methods:

The study includes sixty ARMD patients (20 patients with Wet-ARMD, 20 patients with early Dry ARMD and 20 patients with late Geographic ARMD patients) and twenty healthy subjects as a control group. A venous blood sample were collected from each participant. After centrifuges, the sample will be stored in -70 C for further analysis. The samples were studied with the ELISA method.

Results:

The mean ages of patients with ARMD and control groups were 71.8 and 71.1 years (p = 0.784). The mean PTX3 concentrations were 0.707 ± 0.110 ng/ml in ARMD group and 0.630 ± 0.100 ng/ml in control group (p = 0.009). The mean hCRP levels were 4.032 ± 3.573 mg/L in ARMD group and 3.320 ± 2.628 mg/L in control group (p = 0.493). The mean SAP levels were 111.71 ± 162.37 µg/ml in ARMD group and 182.30 ± 276.82 µg/ml in control group (p = 0.822). İn subgroup analysis, the mean PTX3 concentration difference was only significant between Wet-ARMD group and control group (respectively, 0.726 ± 0.113 and 0.630 ± 0.100 ng/ml, p = 0.03). The difference in the mean hCRP and SAP levels were statistically insignificant between control and ARMD subgroups (respectively, p = 0.615 and p = 0.499).

Conclusions:

PTX3 may have a role in the development of Wet-ARMD. The high level of PTX3 in Wet-ARMD may be related to the inflammatory processes in ARMD pathogenesis.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy